An Open-Label Pilot Study of Esomeprazole in Children With Autism
Status:
Not yet recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Autism is a pervasive developmental disorder characterized by core deficits in social
behavior and communication and the presence of repetitive/stereotyped behaviors. The
objective of the study is to evaluate the efficacy of Esomeprazole as a treatment for social
communication deficits in children with Autism Spectrum Disorder (ASD). This prospective 12
week open-label study will invite 25 children with ASD between the ages of 2 and 6 years of
age to participate.